Hans Biomed Corp · KRX:042520
Hans Biomed — Investor Presentation (March 2023)
31 slides from Hans Biomed's investor presentation, Mar 3, 2023
Slide 1: Investor Relations 2023
HansBiomed Corp. I L Investor Relations 2023
Slide 2: Disclaimer
Disclaimer BABE SASS Hate ALIS|E Presentation dllAle| Be ASS SHOE SAO| SHS (OloHS|Ap”)o] oy ASEH, = ApBO| HHS, SAP EE Epeloll Hot MUZE SAS SASRLIC. = Ate YW & ABS Sot Presentation ASE Oleh] Het “SASS WStora QSLICL Of Bpy{7} OFL! OeHo] Apap Ftr4] AQEM, SAPO] SS ASE ASHS WY MEANS Oo/a + QlOM, HAAS OA’
Slide 3: Chapter 01. Company Overview
Chapter 01. 7/2 7H#2 1) Company Overview — 1-1. Introduction 1-2. History 1-3. Infrastructure 1-4. Corporate governance 2) Product Portfolio
Slide 4: Company Overview - Introduction
Chapter 01. 7/2 7H#2 PtAHTO| On| OF) 1) Company Overview - Introduction CHStEISt ZAI SSt M420) =27|7/2| Nol. 712 Al M7] HHO] 2Ate+S 0|71= Global Leading Company S| APB StAHPO/ ONS FAlS]A} #Ha2 19994 098 15a CHEO|AA =A2eS FAG — OMAIZLAIO|AlAY S! S| 7|7| 7H A! AZ» BhOH = A ABA SP BI28H7, tAws . APA WM
Slide 5: Company Overview - History
Chapter 01. 7/4 742 1) Company Overview Establish Technology +1993 PtAOIC|Z Se(SeAl= Are) ©1999 StAHtO| OnE) Holast ©2002 OFAlOf SICH AAS AT A a Ly AIA behO| AL AH O]=} FDA'S: MALHSS 2S 71 MS +2005 CHettls 15 AAS ME o|7t ANAC R&DAIBS HOS Alatoll R= MSS Innovations +2008 OfAlol 4|z Cla geile = 2H CE
Slide 6: Company Overview - Infrastructure
1. 7[23 7HQ 1) Company Overview StAHO|Qn]& Aas “BA Wa, S3z 7 5 me A +H 20024 (S4 201314) ; (LEAT AMalE}) o Mat ae] 2 /oM|AAL/O| 7/7] + R&D Tissue / Silicone +%Q saaj4 BASH AATB Accreditation ‘BA CN, ez “a8 2019 R&D AEtifo|oojopss 74h +32 GMP Facility AF Smart Factory * stAnjo} “ “Be a, ST *72 1F New
Slide 7: Company Overview - Corporate governance
1) Company Overview - Corporate governance aq | 20114 Aaa + | 328 H Thailand 21 | 20184 ale 4 | 158 #8 | 20194 Ala + | sd 42 | 20194 wale =| 128 Colum 28 | 20204 Hae + | 258 HANS StAuTO/ Qa =F) 8 | 199914 Ale + | 2663 (A'8:74,CH24:192) + 2023.01.02 718 Aq | 20154 Aa + | 368 (aes) | 20184 ousjel + |
Slide 8: Product Portfolio
2)P. ict Portfolio Biologics DZ Medical Device 82,202 Cue (43%) (42%) Soni 27,941 (47%) (47%) olin OS/NS 8448/2H/BSe Sol sks , zee Dental ASE SAMBO AS afeho|a4/0) 3401.4 ofl a[mel go ae As sure he * OLSO|A\zH FHS, SASH S MASO AS Shr etat WSO] Alo] ALS = mm. Silicone Polymer 1,894 3,075 (3%) (5%) ==
Slide 9: Chapter 02. Product Portfolio
Chapter 02. S44! Are 1) Biologics 1-1. Bone graft 1-2. Skin graft 1-3. Sales analysis 1-4. Chinese Market 2) Medical device 2-1. Lifting thread (Mint lift) 2-2. Hair transplant device (Lion) 3) Biocosmetic 3-1. Cosmeceutical (Klardie) 4) Silicon Polymer 4-1. Breast implants (BellaGel) 4-2. Facial im
Slide 10: Biologics — Bone Graft
1)Biologics — Bone Graft » AEF | Sure( Fo Wo. ips | - toa aE ¢€ SureFuse™ (40122) ExFuse™(42x) SureOss® (40124) Genesis™ Sponge (#lulAlA Aziz) DFDBA, Cancellous 2 Carrier= 2tS0/71 SSB O|AM of: Sancellous BoneS| anya ose n gH19|0l| ofa} Be} ZAI7HS) 23-32} HSS E Sponge Ea] SSS ON (A/HE] EOS At ALS AbS
Slide 11: Biologics — Bone Graft
1)Biologics — Bone Graft ATB American Association of Tissue Banks” American Association of Tissue Banks aneBioed Cnprtion Dagon, Reb of Kes « SAUL Qn|=9] ZoAlmi= So1s Holst 27s BZ)o 24 seen ato S004 |Z 01S EASA ClBIS|(AATB)O| TILISIO4 t+ A|BOe SHYAIO|71 O41St Donor MIE At O[+ FDA510K 2/1502 spufah a
Slide 12: Biologics — Skin graft
1)Biologics — Skin graft SureDerm Acellular Dermal Matrix wal Oe m7] BEE AOI OM + Sle oS} EPO WS BAI ALS ts (RTUAS) + 7/% ME cH] RA 40% B7t SureDerm™ UroMax (#012 ¢2%44) - H|7|2} PS/GS NS/OS/URO xia AIS AS A quiet mlz gl spine ge oleH SI m4 ete] ge Bele Al Al SIS 2A Bol Be ga aie I aeee ae
Slide 13: Biologics — Skin graft
1)Biologics — Skin graft BellaCell HD2| 74 at x BellaCell HD thE £0] (ci9l:9 al 100 80 60 40 S N is 0 it 227| 237] 2471 257|(0l4t) 20154 4B Gteh mae 2 BOSS SIS 3! 1|S0|AIaH BS a+eelat + oll S7t Pret SESS myeACHE! NEI] 4 subpectoral~Prepectoral ASI 9] 3} 7|ZEAO| AS Sch lz
Slide 14: Biologics - Sales analysis
1)Biologics - Sales analysis ' (e291: 21 2) ' 322.92 | ~zH 300 : 247| WS 24 254.66 : : 250 248.32. , 200 = 18 x = 1 8 ' =u BONE/SKIN 150 “ s ' : (B2B-2A¢) g te 29% 100 ' 1 ‘ ' 1% : 1 2 SKIN (B2B) 50 t : et 23% © 9991 23710} aa Su BONEIE20) 10% ¥ (202044) (202144) 5 (20224) BONE OB SKIN Base 14
Slide 15: Biologics - Chinese Market
1)Biologics - Chinese Market + AI7+#4 10255 0002484, 221 + iol S43 191200081 Slot at (S191 OF 215042) © SHUG 0000/7H2| ewolss olmet pes © e7/7| AA FS 712 ats ale A(S) HHO SH ASEA| FStSAt +35 BE SST 15,0008 HA] Hatsy| teag 0 + 202514 ANI7| HIBS S17} ete SHE 50% + 202544 WI GIA] atmboy Sz A|2BAt ° BSE
Slide 16: Biologics - Chinese Market
1)Biologics - Chinese Market Sx 27|7| NSS (7|}E8 192k = 1722!) (EI: &) 522 9,0514 632% 5,6234 91% 1,105% 1162 1,8024 + GH: SHOB7I7/LTM, 201984 wT 20144 o|% AMS 20% O|4t AZt 20184 7|Z5,304% o]ot (91% 1H4#) Sa TA S7|7| NSE OHA HSA] Sons 7a] 201414 O|F CAGR 20% 0|4 Sx BOA AS sss 2120 25.0% a r ee eiley
Slide 17: Medical device — Lifting thread
2) Medical device — Lifting thread 360° 3D BY FH AIDE ¥ HIZBA! So] he f MINT Lift® Sts AlOFA, O|=} FDA, & +4074 Olaf 428 Eloy S x +AU 22 WANDS Ae d7} eof ame See Be IS \ ot alm 360° SEI 3D WH] B71 = NMPA S 1071 40\|| 6/7/24 ’ 7 -360° 4] 712 mY] ZspH| DAS|O} pet alse} emp \ Bela XO “CIE MIE afolow So
Slide 18: Medical device — Lifting thread
2) Medical device — Lifting thread H-Faculty + AAA EAS $1St AIA “ai53el 2S POY aia 3,0008 FY BAL ala 3 AIHILH eaem MINT Lift® 4773 O12 St 350 325.46 300 250 227.01 200 150 137,35 ; ug a 14 50 0 il 222| 237| 247] (201944) (202044) (202144) (2022!) a3 Yes Bo213+ pase A241 SOt 311%] HS AAS SRO, SS] O|S
Slide 19: Medical device — Hair transplant device
2) Medical device — Hai splant device (Ebel: 4 2) 20 17.29 Onesepraray OMSL Haren on 217|| 227, 237] 242| AAD wel wAl7ts A ~ (201914) (202014) (202114) (202214)
Slide 20: Cosmeceutical — Klardie
3) Cosmeceutical — Klardie 202241 & AHHEZ| 2] H eH! HeHC Bio-cosmetic Klardie B2}C|Ol] ZA! x xx Betcol 7154 Srtclol] echls 2 as Regenerative Theray BMX WH SSH CHEE ALSAOl Ap ey fee | aa ae + AZAR aaa “gia HB 2H] B7IMIE (HUC-MSCs) HH FO] WL H|EOH OFS ete BL Oley Sel] Alo} DALE SHOAHH FAS ATS ES AAl S
Slide 21: Silicone Polymer
icon Polymer Breast Implant DBELLAGEL Smooth Round base, Smooth surface BELLAGEL smoothFine Round base, SmoothFine surface o HLH AIA AEA] A Hetolo] SAlSt OS Het aS SHE (MFDS)817t 20154 200614 2009'4 ere 20164 ud Q1atarat | NIE O49] 28 H BS Aeoiieeea H 3 NMPA‘I+ 2023 03301E * 202014 wefal ol ead + We
Slide 22: Chapter 03. 1) R&D 2) ATEMs
22 T ZZ im ft =z] Bl tw alt jor fH @ gi _ K! u. a K] #0 Bod gd KO co 0 Chapter 03. 1) R&D 2) ATEMs
Slide 23: |S, th OY Bt S24,
|S, th OY Bt S24, Silicone Polymer MIE Ap /aet Same Sst ADS Mal 79] ALBA 7H A79| Ake BROT AE OTeSS sesl0) x14401 Apo} mo] NEAT SUC elet i] ( mise, wy ACH SS 714 Het «ACH AS NSE { of=7|7] ) 2127/7] 3] 71zt2| + 224, ota Ola Atel DEA EN a eS 4F | Silicone / Lion Product 3F | BONE / Product 2F | SKIN /
Slide 24: R&D
1) R&D - MEO] 2 7|7| SAE} Le OM Ad rips Ato| = 7|7] Saast BS let S|27|7| At St |e a8ct URS AlSMest Ws AR So] WHS Sat AAMAS S FHotD UALICH He Se S7t a|% Sats 7H + MAIL SP AMS Sz + 2314 3&7| MFDS 6{7}<t cs “4%, 1B Nel, pee +e S BEA Wet +2 S7tol Hans Coil loader
Slide 25: ANA MY A1BAI
] ANA MY A1BAI ASatst -AMa| 2 Bae eh THE 2.548 7ef0|O4 Ota S7btE SM) SiN AAAS Melts DE Aol ASR SAH 2021 2023 2025 2027 2029 2031 El: ctors of knee valence, incidence and r #4{ : DatamornitorHealthcare : Osteoarthritis and osteoarthritis pain #4 : Allen,K. D. (2015) “Global, regional p * The Burden o
Slide 26: ie z tas
o a = 5 = 3 ie z tas a) =) Fie ee = PRSts ines + aoe OL ge F 8 | en Bu 4 BB oo <5 gt ol = Al 5 22 — Woe 3a ~ NZ a3 § the § my Rd iz a sy ny ‘ Petia t... — 6 < By” OF 3 =o Ww ee nH Be zx i Ho Rl mies <<) N 3. BNA : A 3 = : 1 IO MS ECL 1a 26 Zl zs AAS Al — 172] =
Slide 27: 202314 BH647} Ollat
202314 40 BH647} Ollat AY ZEA Al StS a 0 2019 20204 2021 2022 20234 20244 20254 202644 20274 2028K1 Meeaas BPHANS —e-HA/eesss le |: 2b ATEM: 201914 7|E HAAS BASU ALS S 53.7% AHA] AZ EA ALS LI] HAFALNIS| SS ZA SIS Yas || GOlst + Ye +0] Z O|AICHS PADI OE ZA 2A 27 * PAL 202214 71% 510% #9] of (PN) | SA
Slide 28: RO iu) 2) Wu ok TW x0 RO | go s Hl Oo |
28 50 RO iu) 2) Wu ok TW x0 50 RO | go s Hl Oo | 50 . | 2 mH * O. | Bo 4 = RO i O!|rFr A
Slide 29: AAO AA} |e! Ara
(201814) (201914) (202014) (202114) (202214) AAO 1 AA} |e! Ara AISAOl HS Atay ool AS SH Be0]2} o1 800 — me a 7454 6704 600 5914 5174 400 200 1032 Reet 134 0 = ” 344 -1974 200 Se 207] 217| 227| 237| 247| 257| (20234) 29
Slide 30: 2022 ESG activities
2) 2022 StAH}O| Sue ESG AS Fel BASH aer}0|a% CSR BAHL QOE, AA}8 BO} Aa ABAAl Us SAt VAMOS BIH NAB Wael DIBA) Seb BIAHO/OOIE EG SS 7158} ty — tas 4 20211 SAHIOQMIS) S2)z}e) MBA, ‘a v lo] be) - A, Ce.Re, -AIGAHS] SHS Sst E7/e alel Sap gl —-« AlsH2Y BA] GIO} AGSt aH |A| wes, ola] BGI HA 9B ALAS Sf / [B
Slide 31: Thank you
Thank you 31